Compare AbCellera Biologics Inc (ABCL) vs Nebius Group NV (NBIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Nebius Group NV — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Nebius Group NV trades at $204.89 (market cap $49.56B). The key difference: Nebius Group NV is far larger — about 21.1× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| ABCL | NBIS | |
|---|---|---|
Market Cap | $2.35B | $49.56B |
Sector | Health | Technology |
52-Week High | $8.12 | $286.69 |
52-Week Low | $2.78 | $44.30 |
Enterprise Value | $1.99B | $49.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
NBIS trades at $213.02, down 1.21% with bearish technical signals despite strong analyst support. The stock shows premium valuations (P/E 82.25, P/S 64.41) but impressive profitability (93.09% net margin) and robust revenue growth projections from $530M to $878M. Recent volatility stems from Meta's potential cloud competition, though news highlights Nebius's AI infrastructure strength and institutional buying interest.
Outlook remains positive with 87.5% analyst buy ratings and $233.13 consensus target, but high valuation and competitive risks from tech giants temper near-term upside. Cash flow trends show aggressive expansion funding, while earnings beats/misses reflect execution volatility in a high-growth sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
